Sunesis Pharmaceuticals Announces Cancellation of Presentation and Webcast at Cowen & Company 38th Annual Health Care Confer...
March 13 2018 - 7:00AM
Cancellation due to Travel Changes Caused by
Inclement Weather
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the
cancellation of the company’s presentation and webcast at the Cowen
& Company 38th Annual Health Care Conference, previously
scheduled to take place today, March 13th, at 8:00 AM Eastern Time
at the Marriott Copley Place in Boston.
Management is no longer able to attend the
conference as planned due to inclement weather in Boston. Willie
Quinn, Chief Financial Officer, and Dayton Misfeldt, Interim Chief
Executive Officer, will hold all scheduled investor meetings as
phone calls. If you are an institutional investor with a scheduled
meeting with Sunesis management, please proceed to your meeting
room at the conference as planned, and reach out to
maeve@argotpartners.com with any questions.
About Sunesis
Pharmaceuticals
Sunesis is a biopharmaceutical company
developing new therapeutics for the treatment of solid and
hematologic cancers. Sunesis has built an experienced cancer drug
development organization committed to improving the lives of people
with cancer. The Company is focused on advancing its novel
kinase-inhibitor pipeline, with an emphasis on establishing proof
of concept that its oral non-covalent BTK-inhibitor vecabrutinib is
effective in ibrutinib-resistant chronic lymphocytic leukemia.
Vecabrutinib is currently being evaluated in a Phase 1b/2 study in
adults with chronic lymphocytic leukemia and other B-cell
malignancies who have progressed after prior therapies. Beyond the
development of vecabrutinib, the Company has two other kinase
inhibitor programs, including the Takeda-partnered pan-RAF
inhibitor TAK-580, which is in clinical trials for solid tumors,
and Sunesis’ proprietary preclinical PDK1 inhibitor SNS-510, which
is in preclinical development with an IND submission planned in
2019. PDK1 is a master kinase that activates other kinases
important to cell growth and survival including members of the AKT,
PKC, RSK and SGK families.
For additional information on Sunesis, please
visit www.sunesis.com.
SUNESIS and the logos are trademarks
of Sunesis Pharmaceuticals, Inc.
Investor and Media
Inquiries: |
|
|
|
|
|
|
|
|
|
Maeve Conneighton |
|
|
|
|
|
|
|
|
Willie
Quinn |
Argot Partners |
|
|
|
|
|
|
|
|
Sunesis
Pharmaceuticals Inc. |
212-600-1902 |
|
|
|
|
|
|
|
|
650-266-3716 |
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Apr 2023 to Apr 2024